Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 1/2 2

Status

Completed 4

Sponsor Class

NETWORK 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Has results × orteronel × Clear all
NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
239 enrolled 38 charts
Genitourinary

Prostatic Neoplasms

NCT01809691 2025-12-31

S1216

SWOG Cancer Research Network

Phase 3 Completed
1,313 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

NCT01193257 2018-12-19

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

Takeda

Phase 3 Completed
1,099 enrolled 32 charts
Genitourinary

Prostatic Neoplasms

NCT01193244 2017-05-17

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Takeda

Phase 3 Completed
1,560 enrolled 35 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡